Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acne Vulgaris-Pipeline Review, H1 2015

Acne Vulgaris-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acne Vulgaris-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acne Vulgaris-Pipeline Review, H1 2015', provides an overview of the Acne Vulgaris's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Acne Vulgaris Overview 10

Therapeutics Development 11

Pipeline Products for Acne Vulgaris-Overview 11

Pipeline Products for Acne Vulgaris-Comparative Analysis 12

Acne Vulgaris-Therapeutics under Development by Companies 13

Acne Vulgaris-Therapeutics under Investigation by Universities/Institutes 16

Acne Vulgaris-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Acne Vulgaris-Products under Development by Companies 20

Acne Vulgaris-Products under Investigation by Universities/Institutes 24

Acne Vulgaris-Companies Involved in Therapeutics Development 25

Advancell 25

Allergan, Inc. 26

AndroScience Corporation 27

Biomar Microbial Technologies 28

Braintree Laboratories, Inc. 29

Brickell Biotech, Inc. 30

Celtaxsys, Inc. 31

Cosmo Pharmaceuticals S.p.A 32

Cutanea Life Sciences 33

Delenex Therapeutics AG 34

Deltanoid Pharmaceuticals Inc. 35

Dermira Inc. 36

ELORAC, Inc. 37

Ensoltek Co., Ltd. 38

Foamix Pharmaceuticals Ltd. 39

Galderma S.A. 40

GlaxoSmithKline plc 41

Helix BioMedix, Inc. 42

Hovione FarmaCiencia SA 43

Kasiak Research Pvt. Ltd. 44

Lee's Pharmaceutical Holdings Limited 45

Maruho Co., Ltd. 46

Nabriva Therapeutics AG 47

Novabiotics Ltd 48

Novan, Inc. 49

OrigImm e.U. 50

Paratek Pharmaceuticals, Inc. 51

Phosphagenics Limited 52

Photocure ASA 53

Provectus Biopharmaceuticals, Inc. 54

QLT Inc. 55

RestorGenex Corporation 56

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 57

Telesso Technologies Limited 58

Thesan Pharmaceuticals, Inc. 59

Toyama Chemical Co., Ltd. 60

Valeant Pharmaceuticals International, Inc. 61

Venn Life Sciences Holdings Plc 62

XBiotech USA, Inc. 63

Xenon Pharmaceuticals Inc. 64

Acne Vulgaris-Therapeutics Assessment 65

Assessment by Monotherapy Products 65

Assessment by Combination Products 66

Assessment by Target 67

Assessment by Mechanism of Action 69

Assessment by Route of Administration 71

Assessment by Molecule Type 73

Drug Profiles 75

(adapalene + benzoyl peroxide)-Drug Profile 75

(adapalene + clindamycin hydrochloride)-Drug Profile 76

Aczone X-Drug Profile 77

AD-037-Drug Profile 78

aminolevulinic acid hydrochloride-Drug Profile 79

ANs-29-Drug Profile 80

ASCJ-9-Drug Profile 81

BBI-3000-Drug Profile 83

BC-7013-Drug Profile 84

becocalcidiol-Drug Profile 85

benzoyl peroxide-Drug Profile 86

benzoyl peroxide-Drug Profile 87

BLI-1100-Drug Profile 88

BPX-01-Drug Profile 89

CB-0301-Drug Profile 90

CB-0604-Drug Profile 92

CTX-4430-Drug Profile 93

DLX-2323-Drug Profile 94

DLX-2681-Drug Profile 95

DRM-01-Drug Profile 96

Drugs for Acne-Drug Profile 97

E-10215-Drug Profile 98

finasteride-Drug Profile 99

GSK-1940029-Drug Profile 100

HB-1345-Drug Profile 101

Hesed-4000-Drug Profile 102

IB-07A037-Drug Profile 103

IDP-120-Drug Profile 104

lemuteporfin-Drug Profile 105

methyl aminolevulinate hydrochloride-Drug Profile 106

minocycline-Drug Profile 108

minocycline-Drug Profile 110

MTC-896-Drug Profile 111

NAI-003-Drug Profile 113

NVN-1000-Drug Profile 114

omiganan pentahydrochloride-Drug Profile 115

onabotulinumtoxin A-Drug Profile 117

ozenoxacin-Drug Profile 118

Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer-Drug Profile 119

PH-10-Drug Profile 120

RA-18C3-Drug Profile 122

Refaglo-Drug Profile 124

RES-440-Drug Profile 125

sarecycline hydrochloride-Drug Profile 126

Small Molecule for Acne-Drug Profile 128

Small Molecule for Acne and Inflammatory Skin Diseases-Drug Profile 129

SYN-1113-Drug Profile 131

Synthetic Peptide for Acne Vulgaris-Drug Profile 132

tretinoin-Drug Profile 133

trifarotene-Drug Profile 135

Vaccine for Acne Vulgaris-Drug Profile 136

Vaccine for Acne Vulgaris-Drug Profile 137

XEN-801-Drug Profile 138

Acne Vulgaris-Recent Pipeline Updates 139

Acne Vulgaris-Dormant Projects 150

Acne Vulgaris-Discontinued Products 157

Acne Vulgaris-Product Development Milestones 158

Featured News & Press Releases 158

Appendix 166

Methodology 166

Coverage 166

Secondary Research 166

Primary Research 166

Expert Panel Validation 166

Contact Us 166

Disclaimer 167

List of Tables

Number of Products under Development for Acne Vulgaris, H1 2015 14

Number of Products under Development for Acne Vulgaris-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Development by Companies, H1 2015 (Contd..3) 26

Products under Investigation by Universities/Institutes, H1 2015 27

Acne Vulgaris-Pipeline by Advancell, H1 2015 28

Acne Vulgaris-Pipeline by Allergan, Inc., H1 2015 29

Acne Vulgaris-Pipeline by AndroScience Corporation, H1 2015 30

Acne Vulgaris-Pipeline by Biomar Microbial Technologies, H1 2015 31

Acne Vulgaris-Pipeline by Braintree Laboratories, Inc., H1 2015 32

Acne Vulgaris-Pipeline by Brickell Biotech, Inc., H1 2015 33

Acne Vulgaris-Pipeline by Celtaxsys, Inc., H1 2015 34

Acne Vulgaris-Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 35

Acne Vulgaris-Pipeline by Cutanea Life Sciences, H1 2015 36

Acne Vulgaris-Pipeline by Delenex Therapeutics AG, H1 2015 37

Acne Vulgaris-Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 38

Acne Vulgaris-Pipeline by Dermira Inc., H1 2015 39

Acne Vulgaris-Pipeline by ELORAC, Inc., H1 2015 40

Acne Vulgaris-Pipeline by Ensoltek Co., Ltd., H1 2015 41

Acne Vulgaris-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 42

Acne Vulgaris-Pipeline by Galderma S.A., H1 2015 43

Acne Vulgaris-Pipeline by GlaxoSmithKline plc, H1 2015 44

Acne Vulgaris-Pipeline by Helix BioMedix, Inc., H1 2015 45

Acne Vulgaris-Pipeline by Hovione FarmaCiencia SA, H1 2015 46

Acne Vulgaris-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 47

Acne Vulgaris-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 48

Acne Vulgaris-Pipeline by Maruho Co., Ltd., H1 2015 49

Acne Vulgaris-Pipeline by Nabriva Therapeutics AG, H1 2015 50

Acne Vulgaris-Pipeline by Novabiotics Ltd, H1 2015 51

Acne Vulgaris-Pipeline by Novan, Inc., H1 2015 52

Acne Vulgaris-Pipeline by OrigImm e.U., H1 2015 53

Acne Vulgaris-Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 54

Acne Vulgaris-Pipeline by Phosphagenics Limited, H1 2015 55

Acne Vulgaris-Pipeline by Photocure ASA, H1 2015 56

Acne Vulgaris-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 57

Acne Vulgaris-Pipeline by QLT Inc., H1 2015 58

Acne Vulgaris-Pipeline by RestorGenex Corporation, H1 2015 59

Acne Vulgaris-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 60

Acne Vulgaris-Pipeline by Telesso Technologies Limited, H1 2015 61

Acne Vulgaris-Pipeline by Thesan Pharmaceuticals, Inc., H1 2015 62

Acne Vulgaris-Pipeline by Toyama Chemical Co., Ltd., H1 2015 63

Acne Vulgaris-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 64

Acne Vulgaris-Pipeline by Venn Life Sciences Holdings Plc, H1 2015 65

Acne Vulgaris-Pipeline by XBiotech USA, Inc., H1 2015 66

Acne Vulgaris-Pipeline by Xenon Pharmaceuticals Inc., H1 2015 67

Assessment by Monotherapy Products, H1 2015 68

Assessment by Combination Products, H1 2015 69

Number of Products by Stage and Target, H1 2015 71

Number of Products by Stage and Mechanism of Action, H1 2015 73

Number of Products by Stage and Route of Administration, H1 2015 75

Number of Products by Stage and Molecule Type, H1 2015 77

Acne Vulgaris Therapeutics-Recent Pipeline Updates, H1 2015 142

Acne Vulgaris-Dormant Projects, H1 2015 153

Acne Vulgaris-Dormant Projects (Contd..1), H1 2015 154

Acne Vulgaris-Dormant Projects (Contd..2), H1 2015 155

Acne Vulgaris-Dormant Projects (Contd..3), H1 2015 156

Acne Vulgaris-Dormant Projects (Contd..4), H1 2015 157

Acne Vulgaris-Dormant Projects (Contd..5), H1 2015 158

Acne Vulgaris-Dormant Projects (Contd..6), H1 2015 159

Acne Vulgaris-Discontinued Products, H1 2015 160

List of Figures

Number of Products under Development for Acne Vulgaris, H1 2015 14

Number of Products under Development for Acne Vulgaris-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 68

Assessment by Combination Products, H1 2015 69

Number of Products by Top 10 Targets, H1 2015 70

Number of Products by Stage and Top 10 Targets, H1 2015 70

Number of Products by Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Top 10 Routes of Administration, H1 2015 74

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 75

Number of Products by Top 10 Molecule Types, H1 2015 76

Number of Products by Stage and Top 10 Molecule Types, H1 2015 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advancell

Allergan, Inc.

AndroScience Corporation

Biomar Microbial Technologies

Braintree Laboratories, Inc.

Brickell Biotech, Inc.

Celtaxsys, Inc.

Cosmo Pharmaceuticals S.p.A

Cutanea Life Sciences

Delenex Therapeutics AG

Deltanoid Pharmaceuticals Inc.

Dermira Inc.

ELORAC, Inc.

Ensoltek Co., Ltd.

Foamix Pharmaceuticals Ltd.

Galderma S.A.

GlaxoSmithKline plc

Helix BioMedix, Inc.

Hovione FarmaCiencia SA

Kasiak Research Pvt. Ltd.

Lee's Pharmaceutical Holdings Limited

Maruho Co., Ltd.

Nabriva Therapeutics AG

Novabiotics Ltd

Novan, Inc.

OrigImm e.U.

Paratek Pharmaceuticals, Inc.

Phosphagenics Limited

Photocure ASA

Provectus Biopharmaceuticals, Inc.

QLT Inc.

RestorGenex Corporation

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Telesso Technologies Limited

Thesan Pharmaceuticals, Inc.

Toyama Chemical Co., Ltd.

Valeant Pharmaceuticals International, Inc.

Venn Life Sciences Holdings Plc

XBiotech USA, Inc.

Xenon Pharmaceuticals Inc.

Acne Vulgaris Therapeutic Products under Development, Key Players in Acne Vulgaris Therapeutics, Acne Vulgaris Pipeline Overview, Acne Vulgaris Pipeline, Acne Vulgaris Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com